Onsenal withdrawn

Pfizer has withdrawn Onsenal (celecoxib) after concluding that it is unable to meet the conditions of the product’s marketing authorisation.

Onsenal was launched in June 2010 as an adjunct to surgery and further endoscopic surveillance in the treatment of familial adenomatous polyposis. Approval for this rare condition was granted on the basis of data showing a reduction in polyp number following treatment with the COX-2 inhibitor. At the time of approval the EMA requested that the manufacturer provide post-approval data on clinically relevant efficacy outcomes. The long-term placebo-controlled Children’s International Polyposis trial was initiated in response to this request, but the trial has progressed too slowly to meet its enrolment goals. Celecoxib remains available as Celebrex for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Further Information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases